# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Mark Massaro downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Neutral to Sell.
Morgan Stanley analyst Tejas Savant maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Equal-Weight and lowers the price t...
Ginkgo's Class A Common Stock continues to trade on the NYSEBOSTON, May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, ...
William Blair analyst Matt Larew downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Market Perform to Underperform.
Ginkgo Bioworks reported quarterly sales of $38 million which missed the analyst consensus estimate of $46.044 million by 17.47...